Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Pharmacogenetic Testing Market Expected To Reach $29.54 Billion By 2030 At 15.5% CAGR
The pharmacogenetic testing sector has experienced significant expansion in recent years, with its market value projected to rise from $14.33 billion in 2025 to $16.58 billion in 2026, reflecting a compound annual growth rate of 15.7%. Key drivers behind this historical growth include improvements in genomic sequencing techniques, heightened awareness regarding adverse drug reactions, an increasing prevalence of chronic diseases, reduced expenses associated with genetic testing, and a growing understanding of clinical applications.
The pharmacogenetic testing market is projected to expand significantly in the coming years. By 2030, its value is anticipated to reach $29.55 billion, representing a compound annual growth rate (CAGR) of 15.5%. This anticipated expansion is fueled by developments such as the advancement of precision healthcare, the broadening of direct-to-consumer testing services, the incorporation of data into electronic health records, heightened regulatory backing, and increased funding for genomics research. Key trends shaping the forecast period encompass a growing embrace of personalized medicine, more frequent use of genetic assessments to inform drug choices, extended applications in oncology and cardiology, heightened demand for precise diagnostic tools, and the broader integration of pharmacogenomics into routine medical practice.
Download A Free Sample Report For Comprehensive Market Insights:
Pharmacogenetic Testing Market Development Factors: Which Trends Are Supporting Demand?
The rising need for tailored medical approaches is anticipated to boost the pharmacogenomic testing industry moving forward. Personalized or precision medicine involves a healthcare strategy that customizes treatments and medical choices based on an individual’s distinct genetic, biological, and lifestyle factors. This approach is gaining traction because it enhances therapeutic results, aids in early diagnosis, and improves cost efficiency in patient management. The pharmacogenomic testing sector facilitates personalized medicine by examining a person’s genetic makeup to forecast drug reactions, allowing for refined therapy choices and lowering the chance of harmful side effects. As an example, in February 2024, the Personalized Medicine Coalition (PMC), a non-profit organization in the U.S., reported that the FDA authorized 16 novel personalized therapies for uncommon diseases in 2023, up from 6 approvals in 2022. Consequently, the growing uptake of personalized medicine is fueling the expansion of the pharmacogenomic testing market.
Pharmacogenetic Testing Market Segment Outlook: Which Categories Are Expanding The Fastest?
The pharmacogenetic testing market covered in this report is segmented –
1) By Type: Whole Genome Sequencing, Whole Exome Sequencing, Array-Based Tests, Single Gene Tests
2) By Drug Type: Prescription Drugs, Nutraceuticals, Recreational Drugs, Herbal Supplements, Vitamins, Over-The-Counter Medications
3) By Therapeutic Area: Cardiology, Gastroenterology, Anesthesiology, Genomics, Endocrinology, Immunology And Hypersensitivity, Dermatology, Gynecology, Oncology, Other Therapeutic Areas
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacies, Mail-Order Pharmacies, Direct-to-Customer Services
5) By End User: Healthcare Providers, Pharmaceutical And Biotechnology Companies, Centers And Academic Institutes, Other End Users
Subsegments:
1) By Whole Genome Sequencing: Illumina Sequencing, Ion Torrent Sequencing, Pacific Biosciences Sequencing, Oxford Nanopore Sequencing
2) By Whole Exome Sequencing: Capture-Based Exome Sequencing, Targeted Enrichment Exome Sequencing, Hybridization-Based Exome Sequencing
3) By Array-Based Tests: SNP Array Testing, Expression Array Testing, Copy Number Variation Array Testing
4) By Single Gene Tests: Targeted Gene Panels, Mutation Detection Tests, Sequencing Of Specific Genes
Pharmacogenetic Testing Market Transformation Trends: Which Innovations Are Driving Change?
Leading players in the pharmacogenetics testing market are prioritizing the creation of sophisticated pharmacogenomics services, like prescription-based tests, aimed at boosting medication safety, refining treatment accuracy, and aiding personalized therapy choices. This type of testing involves genetic assessments requested by authorized medical professionals to determine how a person’s genetic profile impacts their reaction to particular drugs, enabling practitioners to enhance drug selection and dosage while cutting down the chance of adverse events. A notable example from May 2023 is UCSF, a healthcare organization based in the United States, which introduced its pharmacogenomics testing service to advance the precision of medical care, offering clinicians genetic data that facilitates tailoring drug regimens to each patient’s individual characteristics, improves drug effectiveness, and lowers the potential for serious side effects.
Pharmacogenetic Testing Market Key Companies And Competitive Benchmarking
Major companies operating in the pharmacogenetic testing market are CVS Health Corporation, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Eurofins Scientific Inc., Bio-Rad Laboratories, Precision Medicine Advsiors, Azenta Life Sciences, Fulgent Genetics, Pacific Biosciences of California Inc., Castle Biosciences, 23andMe Holding Co., Helix Inc., Genomind Inc., MD Labs, Sonic Genetics, AutoGenomics Inc., LabClinics SA, Gene By Gene Ltd., Xcode Life Sciences, YouScript, RxGenomix LLC
Access The Complete Pharmacogenetic Testing Market Report:
Pharmacogenetic Testing Market Leading Geography: Which Region Generates The Most Revenue?
Asia-Pacific was the largest region in the pharmacogenetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model